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Abstract
Introduction: Osteoarthritis is the most prevalent chronic non-infective joint
arthritis. Because of its chronic disease nature, local drugs are preferred due to
lower complications. In the present study, the new herbal pomade Marhame-
Mafasel for knee osteoarthritis was used in a double-blind crossover trial. 
The aim of the study was to assess the efficacy and safety of Marhame-Mafasel
pomade, which consists of several medical herbs including Arnebia euchroma
and Matricaria chamomilla, in osteoarthritis of the knee.
Material and methods: This study was a placebo-controlled double-blind
crossover trial. Forty-two patients with pain associated with osteoarthritis of
the knee (diagnosed by criteria of the European League against Rheumatism
and physical examination) were drawn from patients attending the Clinic of
Mostafa-Khomeini Hospital. In this study we assessed efficacy (analgesic effect
and improved function) of herbal pomade Marhame-Mafasel, which was used
locally in patients with primary osteoarthritis of the knee over three weeks. The
instrument of the study was the Western Ontario and McMaster Universities
(WOMAC) LK3.1 standard questionnaires.
Results: The participants in each group were 21 patients; 30 (71.4%) were women
and 12 (28.6%) of them were men. The participants were between 40 and 76
years old. Six patients had mild arthritis, 15 had moderate arthritis and 21 had
severe arthritis. The positive analgesic effect of the herbal pomade Marhame-
Mafasel in primary knee osteoarthritis was proven. The herbal joint pomade
Marhame-Mafasel had a significantly greater mean change in score compared
to the placebo group for osteoarthritis severity (p < 0.05).
Conclusions: Herbal pomade Marhame-Mafasel in comparison to placebo has
more effect on reduction of pain of primary knee osteoarthritis.
Key words: osteoarthritis, herbal medicine, non-compliance, principal component
analysis
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Osteoarthritis, or degenerative joint disease,
occurs when the cushiony cartilage between two
bones becomes worn down, and the bones begin
to rub against each other in the joint (the area
where two bones come together) [1].
This often leads to pain, swelling, a decrease in
motion at the joint, stiffness, or the formation of
bone spurs (tiny growths of new bone) [1].
Osteoarthritis is the most prevalent chronic non-
infective joint arthritis and approximately 25% of
people aged 55 or above have knee pain almost
every day [2]. The prevalence of this disease in
women is greater than in men [3, 4] and there is
a significant positive correlation between age and
osteoarthritis of the knee [3]. The prevalence 
of osteoarthritis of the knee in the U.S. is
approximately 0.9% (1.2% in women and 0.4% in
men) [5]. Osteoarthritis in the knee is one of the
main causes which lead to impaired mobility in the
elderly [6]. Many patients with knee pain have
limitations in their physical functions which prevent
them from engaging in their usual daily activities.
Drugs frequently used in osteoarthritis are
analgesics, cartilage protective drugs and steroidal
and non-steroidal anti-inflammatory drugs (NSAID).
In addition, there are many pharmacological,
supportive and surgical treatment options which
depend on the disease severity. Because it is
a chronic disease, local drugs are preferred due to
lower complications. As steroidal and non-steroidal
anti-inflammatory drugs have systemic side effects
such as digestive and renal impairment, they should
be used carefully [7]. Local drugs such as pomade,
cream, gel, etc., are simply used. Thus, preparing
pomade to reduce pain and disability of patients is
very important. Despite the long history of herbal
medicine in Iran, only a few studies have been
carried out to investigate the effect of herbal
medication on osteoarthritis. Therefore, due to the
necessity of appropriate treatments to decrease
pain of patients suffering from osteoarthritis, a new
herbal pomade for osteoarthritis of the knee in
a double-blind clinical trial was used.  
Material and methods
Participants and inclusion/exclusion criteria
The study was a double-blind randomized
crossover trial with two treatments and two periods
in 42 osteoarthritis patients. In this study,
participants were referred to the orthopaedic clinic
of Mostafa-Khomeini Hospital in Tehran. The
protocol was approved by the Research Ethics
Committee at Shahed University, Tehran. In
addition, before starting the study, patients signed
an informed consent form according to the Helsinki
Declaration. Inclusion criteria specified non-
pregnant women and age 40-80 years, with primary
osteoarthritis of at least one knee. Patients 
were eligible for the study if they had pain
associated with osteoarthritis of the knee
(diagnosed by criteria of the European League
against Rheumatism and physical examination) 
[8, 9]. Patients with acute arthritis of the knee 
or secondary arthritis related to systemic
inflammatory arthritis (including rheumatoid
arthritis, post-infectious arthritis and metabolic
arthritis, psoriatic arthritis, traumatic arthritis or
surgical joint replacement) were excluded from the
study. 
Intervention and randomization
Marhame-Mafasel pomade (MM) consisted of
several medical herbs (including Arnebia euchroma
and Matricaria chamomilla) and was made by the
pharmacology division of Shahed University, Iran;
its formula is at the pharmacology division of
Shahed University. Marhame-Mafasel pomade and
placebo were inserted into similar tubs by
a pharmaceutical firm.
At the start of the study, participants underwent
a comprehensive physical examination, and
a medication history was taken by a physician.
Patients were randomized according to a random
number table to receive either Marhame-Mafasel
pomade or placebo. In the first sequence, 21
participants in the treatment arm received
Marhame-Mafasel pomade (herbal medication)
followed by placebo; and in the second sequence,
21 patients received placebo followed by Marhame-
Mafasel pomade. Subjects were instructed to apply
1.5 g of pomade every 8 hours over six weeks,
massaging it firmly into the skin until it disappeared
completely. After three weeks subjects were
assessed and researchers completed questionnaires
at periods. 
Outcome measures
Subjects were evaluated in terms of three
components (pain score ranged from 0 (no pain) to
100 (extreme pain); physical function score ranged
from 0 (no difficulty) to 100 (extreme difficulty);
stiffness score ranged 0 (no stiffness) to 100
(extreme stiffness)) at the end of both periods I
and II. These components were measured by the
Western Ontario and McMaster Universities
osteoarthritis index (WOMAC), which is a validated
questionnaire [10] consisting of 24 questions (5 on
pain, 17 on physical function and 2 on stiffness),
each scored on a 5-point Likert scale. After a one-
week wash-out period, participants received the
opposite treatment in period II and researchers
completed the WOMAC questionnaire again for
each patient. The secondary measure was severity
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components (pain, physical function and stiffness
scores) that ranged from 0 (no pain) to 100
(extreme pain). In the study, a subject's observed
compliance level was classified to an ordinal
variable based on the amount of pomade in tubes
taken by the patient. A patient was considered to
comply (Compliance) with the assigned treatment
if more than 75% of the pomade in the tubes was
taken and moderate compliance if 25-75% of the
pomade in the tubes was taken. Otherwise the
subject's observed compliance to the assigned
treatment was classified as poor compliance (if less
than 25% of pomade in the tubes was taken). 
Safety analysis
Safety was assessed during all weekly clinic visits
and telephone visits by physicians. Safety variables
included: adverse events, which were identified
using a checklist covering common oral NSAID
(non-steroidal anti-inflammatory drugs) side effects;
application site dermatological reactions and vital
signs, which was based on standard predictive
testing [11], and any abnormality was recorded as
an adverse event.
Statistical analysis
We used principle component analysis and made
a linear compound from three components (pain,
physical function and stiffness scores), namely
severity of osteoarthritis, which ranged from 0 (no
disease) to 100 (extreme disease). Data for the
Marhame-Mafasel pomade and placebo were
analysed corresponding to the new response
variable, severity of osteoarthritis. Since in our study
there were moderate and poor compliance, we
estimated treatment effects given compliance levels
that we considered moderate and poor compliance
as non-compliance in the final analysis. Chi-square
test and Fisher's exact test (for small numbers) were
used to compare categorical baseline demographic
differences and t-test was used to compare average
differences. The continuous variable (severity of
pain, which was a linear compound from pain,
physical function and stiffness scores) was analysed
by ANCOVA with baseline scores and compliance
level as the covariate. All statistical tests were two-
sided and were performed at the 0.05 level of
significance. Statistical analysis was performed with
SAS Institute Inc. Version 9.1 (2002). 
Results
The 42 patients enrolled in the present study
were randomized to treatment with either
Marhame-Mafasel pomade (n = 21) or placebo 
(n = 21). All patients were followed to the end of
the study. Participants in active treatment and
placebo did not have access to the opposite
treatment. There were no missing data, loss to
follow-up or withdrawal. Thirty (71.4%) subjects
were women and 12 (28.6%) were men (Table I).
Age of patients was 40-76 years (Table 1). During
the trial, some patients had moderate or poor
compliance (Table II). More patients in the
Marhame-Mafasel group (83.3%) completed the
entire 6-week treatment period compared to the
placebo group (78.6%, p < 0.05), while dropout and
discontinuation did not occur in the entire study.
There was no significant difference between
treatment groups in baseline characteristics (Table I;
p > 0.05). One third of participants had a family
history of arthritic joints. In our study, based on
clinical symptoms and results of radiography, 
Placebo Marhame-Mafasel p
Age [years]a 58.48 ±10.25 58.56 ±10.6 0.979
Weight [kg]a 75.81 ±17.58 69.56 ±10.97 0.138
Height [m]a 1.58 ±0.08 1.64 ±0.09 0.023
Parity [number]a 4.57 ±1.91 3.85 ±2.1 0.229
BMI [kg/m2]a 30.26 ±6.18 25.77 ±3.89 0.004
Education (illiterate) [%] 75.81 69.55 0.074
Sex (female) [%] 81 75.6 0.064
Pain scorea 50 ±21.6 41.63 ±25.4 0.236
Physical function scorea 40 ±26.48 63.9 ±40.1 0.61
Stiffness scorea 81.77 ±26.48 63.95 ±40.1 0.085
Severity of disease score*a 48.8 ±13.94 38.3 ±21.16 0.08
aData are presented as mean ± SD
*Severity of disease score was a component of pain, physical function and stiffness scores by principle component analysis, ranging from 
0 (no osteoarthritis) to 100 (extreme osteoarthritis)
Table I. Baseline demographics and characteristics of patients in placebo and Marhame-Mafasel groups
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II I
Placebo followed by Marhame-Mafasel Poor compliance (< 25%) 2 (0.09) 1 (0.05) 3 (0.07)
Moderate compliance (25-75%) 3 (0.14) 3 (0.14) 6 (0.14)
Compliance (≥ 75%) 16 (0.76) 17 (0.81) 33 (0.79)
Total 21 21 42
Marhame-Mafasel followed by placebo Poor compliance (< 25%) 1 (0.05) 1 (0.05) 2 (0.05)
Moderate compliance (25-75%) 2 (0.09) 3 (0.14) 5 (0.12)
Compliance (≥ 75%) 18 (0.86) 17 (0.81) 35 (0.83)
Total 21 21 42
* I – the first period (or first three weeks) of the study, II – the second period (or second three weeks) of the study after a one-week washout
period
Table II. Distribution of patient compliance in two periods and two sequences of the study
Efficacy variable Treatment group N Change in score, mean (SD)
Period I – baseline (A) Period II – baseline (B)
Pain score Placebo 21 –8.38 (21.83) –7.48 (18.88)
MM 21 –14 (18.44)a –14.48 (21.46)a
Physical function score Placebo 21 –9.28 (14.17)a –8.33 (27.91)a
MM 21 –10.37 (13.29)a –15 (20)a
Stiffness score Placebo 21 –6.82 (15.28) –10.72 (24.38)
MM 21 –21.12 (28.73)a –24.04 (31.69)
Severity of disease score Placebo 21 –4.82 (15.28) –4.72 (15.69)
MM 21 –10.83 (16.63)a –11.39 (18.34)a
MM – Marhame-Mafasel pomade; (A) and (B) show mean difference of change in score before intervention (baseline score) and after intervention
in first and second periods, respectively; 
21
Σ (intervention scorek – baseline scorek)
k=1 where A, B =
21
Table III. Efficacy evaluation of continuous variables
6 (14%) patients had mild arthritis, 15 (36%)
patients had moderate arthritis, and 21 (50%)
patients had severe arthritis, which were not
significantly different between treatment groups 
(p > 0.05). Mean body mass index was 28.2 (BMI for
men and women was 26 and 29, respectively).
Approximately 60% of participants skipped from
stairs and 13% of them had heavy work each day.
More than half of patients (56%) did not 
have efficient mobility and daily routine sport
programming. After treatment, there was
a significant difference between Marhame-Mafasel
and placebo effects (p < 0.05) for pain, physical
function, stiffness and disease severity in both
periods I and II. In our study we showed an effect
size of 0.40 for pain reduction, 0.32 and 0.38 for
improving physical function and stiffness,
respectively. In this study, compliance to assigned
drug dosage among participants was divided into
three categories (Table II). In this study, we did not
observe a carry-over effect (p = 0.063). The results
indicated that Marhame-Mafasel pomade in
comparison with placebo had more positive effects
on decreasing the knee pain of arthritic disease
when the patient did not show complete
compliance with the treatment. However, adjusted
results based on compliance levels showed that
Marhame-Mafasel pomade had a significantly
greater effect on reduction of disease-associated pain
severity in comparison with placebo (Tables III, IV). 
Discussion
Osteoarthritis is the most prevalent chronic non-
infective joint arthritis and it does not have an
absolute remedy. The existing oral and injected
treatments have systemic side effects such as
digestive and renal impairment entailing that they
must not be consumed over a long period.
Marhame-Mafasel pomade has no internal side
effects such as digestive and renal impairment. This
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piroxicam gel, diclofenac ointment and comfrey root
extract ointment [12-22]; on the other hand, we
found a significant difference between Marhame-
Mafasel and placebo in pain relief for patients with
knee osteoarthritis (p < 0.05). Since capsaicin
ointment (chili extract) had skin and mucoid side
effects, it appears that Marhame-Mafasel pomade
was more tolerable, because it had no major local
side effects (Table V) such as intolerable itch and
blebs [23, 24]. In the study, efficacy of Marhame-
Mafasel pomade in comparison to placebo in
decreasing painful osteoarthritis of the knee was
shown, while the efficacy of copper-salicylate gel
was similar to placebo effects (p > 0.05) in
a previous study [21]; also, copper-salicylate gel
occasionally had severe side effects [19, 21]. In line
with the findings of other studies [8], in our study
the majority of participants were women. The result
was confirmed by other studies [25]. We calculated
an effect size of 0.40 for pain reduction, 0.32 for
improving physical function, and 0.38 for stiffness.
Baer  et al. in a study of diclofenac effect on
treatment of knee osteoarthritis calculated a pooled
effect size of 0.41 for pain relief, 0.44 for improved
physical function, and 0.43 for stiffness [26]. Lin et
al. calculated a pooled effect size of 0.04 for pain
reduction [25]. Lee et al., in a meta-analysis of 
14 osteoarthritis trials, found a pooled effect size of
0.37 for pain reduction with oral NSAIDs [27]. Zhang
et al., using data from 2 oral NSAID studies,
calculated a pooled effect size for osteoarthritis pain
reduction of 0.34 [28]. The results showed that
herbal joint pomade (Marhame-Mafasel) had no
harmful side effects. The data in this report provide
substantial evidence for the efficacy and safety of
herbal joint pomade Marhame-Mafasel solution in
chronic osteoarthritis of the knee.
A criticism of the study may be that some
patients had non-compliance with the assigned
treatment. The main reason for non-compliance
was participants' forgetfulness.
The Marhame-Mafasel pomade has benefit in
treatment of knee osteoarthritis without any major
local reactions.
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Sequence or groupP eriod I, mean (SD) Period II, mean (SD) Treatment effect, mean (SD)
Placebo followed by MM 38.45 (16.27) 31.61 (16.17) 3.94* (2.01)
MM followed by placebo 33.73 (22.41) 37.93 (19.94)
* P < 0.05; SD – standard deviation; MM – Marhame-Mafasel pomade
Table IV. Outcomes in different periods and groups
Marhame-Mafasel pomade (n = 42) Placebo (n = 42)
Withdrew before treatment, n (%) 0 (0) 0 (0)
Withdrew during trial, n (%) 0 (0) 0 (0)
Number of adverse reactions, n (%)
Skin 2 (4.76)* 0 (0)
Miscellaneous 0 (0) 0 (0)
Number of actions taken, n (%)
Treatment lacked efficacy 0 (0) 0 (0)
Treatment discontinued 0 (0) 0 (0)
Treatment interrupted 0 (0) 0 (0)
Concomitant illness, n (%) 0 (0) 0 (0)
Lost to follow-up, n (%) 0 (0) 0 (0)
Partial compliance, n (%) 7 (16.7) 9 (21.4)
*Skin reaction was not major and was treated by drug
Table V. Comparison of treatment and placebo groups in a trial of mixture of Arnebia euchroma and Matricaria
chamomilla pomade for pain relief of osteoarthritis of the knee
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